Table 3 Risk of cardiovascular events by the deep-learning-based retinal CVD biomarker (Reti-CVD) in participants who had 7.5–10% QRISK3 score
QRISK3 | Reti-CVDa | N | Cases | Person-years | Incidence rate at year 10 (95% CI) |
|---|---|---|---|---|---|
Non-statin cohort (n = 45,473) | |||||
 ≥ 5 to < 7.5 |  | 7842 | 478 | 83,295 | 5.6 (5.1–6.1) |
 ≥ 7.5 to < 10 | Low | 652 | 47 | 6868 | 7.2 (5.4–9.6) |
 ≥ 7.5 to < 10 | Moderate | 4526 | 401 | 47,286 | 7.9 (7.1–8.8) |
 ≥ 7.5 to < 10 | High | 518 | 62 | 5318 | 11.5 (8.9–15.0) |
 ≥ 10 to < 12.5 |  | 3353 | 394 | 34,314 | 11.0 (9.9–12.2) |
Total |  | 16,891 | 1382 | 177,081 | 7.8 (7.4–8.2) |
Stage 1 Hypertension cohort (n = 11,966) | |||||
 ≥ 5 to < 7.5 |  | 2622 | 154 | 27,891 | 5.5 (4.6–6.5) |
 ≥ 7.5 to < 10 | Low | 230 | 16 | 2427 | 6.8 (4.1–11.3) |
 ≥ 7.5 to < 10 | Moderate | 1525 | 143 | 15,821 | 8.3 (6.9–9.9) |
 ≥ 7.5 to < 10 | High | 186 | 22 | 1903 | 11.5 (7.4–17.8) |
 ≥ 10 to <1 2.5 |  | 974 | 115 | 9990 | 10.9 (9.0–13.3) |
Total |  | 5537 | 450 | 58,032 | 7.8 (7.1–8.5) |
Middle–aged cohort (40 to 64 years, n = 38,941) | |||||
 ≥ 5 to < 7.5 |  | 7097 | 442 | 75,354 | 5.7 (5.2–6.3) |
 ≥ 7.5 to < 10 | Low | 497 | 30 | 5291 | 5.8 (4.0–8.4) |
 ≥ 7.5 to < 10 | Moderate | 2856 | 272 | 29,813 | 8.5 (7.5–9.7) |
 ≥ 7.5 to < 10 | High | 287 | 43 | 2914 | 14.2 (10.3–19.5) |
 ≥ 10 to < 12.5 |  | 1327 | 153 | 13,658 | 11.2 (9.5–13.2) |
Total |  | 12,064 | 940 | 127,030 | 7.4 (6.9–7.9) |